Evidence map›Paper›PMID 38076040›Full record

ArticleHeliyon2023

Exploring the molecular mechanism of Licorice rose beverage anti-melasma based on network pharmacology, molecular docking technology and in vivo and in vitro experimental verification.

Dan Zhai, Yi Hu, Li Liu, Zhuxian Wang, Peiyi Liang, CuiPing Jiang, Hui Li, Quanfu Zeng, Hongkai Chen, Yufan Wu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Dan ZhaiDepartment of Pediatrics, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
Yi HuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Li LiuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Zhuxian WangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Peiyi LiangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
CuiPing JiangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Hui LiDepartment of Traditional Chinese Medicine, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, 510220, China.
Quanfu ZengSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Hongkai ChenSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yufan WuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yinglin GuoSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yankui YiSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Chunyan ShenSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Qiang LiuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Hongxia ZhuDepartment of Pediatrics, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
Southern Medical University · CNTCM-Intigrated Cancer Center of Southern Medical University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melasma is a pigmentation disease with refractory and high recurrence risk. Therefore, finding effective treatment has become the focus of research. This study aimed to reveal the mechanism of Licorice rose beverage (LRB) in treating melasma from the perspective of network pharmacology and in vitro and in vivo experimental techniques. Network pharmacological studies have shown that Isolicoflavonol, quercetin, and kaempferol are the main active components of anti-melasma and tyrosinase is the main target. Molecular docking studies have shown that these compounds have a good affinity for these targets. In vitro tyrosinase inhibition experiments showed that LRB could significantly inhibit tyrosinase activity. In vivo studies showed that LRB could significantly improve skin damage and skin pigmentation, reduce the activities of serum and skin tyrosinase in model mice, increase the activity of SOD in serum, and reduce the content of MDA in mice, showing a good effect of anti-melasma. In conclusion, these findings reveal the molecular mechanism of LRB in treating melasma and provide the scientific basis for this product's development and clinical application.

Indexed as

Licorice rose beverageMelasmaNetwork pharmacologyTyrosinase

Identifiers

PMID38076040
PMCPMC10709401
OpenAlexW4388751491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.